| Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) MS Capehorn, AM Catarig, JK Furberg, A Janez, HC Price, S Tadayon, ... Diabetes & metabolism 46 (2), 100-109, 2020 | 350 | 2020 |
| Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b … I Lingvay, AM Catarig, JP Frias, H Kumar, NL Lausvig, CW le Roux, ... The lancet Diabetes & endocrinology 7 (11), 834-844, 2019 | 246 | 2019 |
| Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial RJ McCrimmon, AM Catarig, JP Frias, NL Lausvig, CW le Roux, D Thielke, ... Diabetologia 63, 473-485, 2020 | 87 | 2020 |
| Use and effectiveness of a fixed‐ratio combination of insulin degludec/liraglutide (IDegLira) in a real‐world population with type 2 diabetes: results from a European … H Price, M Blüher, R Prager, TM Phan, BL Thorsted, B Schultes, ... Diabetes, Obesity and Metabolism 20 (4), 954-962, 2018 | 78 | 2018 |
| AE uropean, multicentre, retrospective, non‐interventional study (EU‐TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 … T Siegmund, N Tentolouris, ST Knudsen, A Lapolla, R Prager, TM Phan, ... Diabetes, Obesity and Metabolism 20 (3), 689-697, 2018 | 67 | 2018 |
| Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study NR Ekberg, U Bodholdt, AM Catarig, SB Catrina, K Grau, CN Holmberg, ... Primary Care Diabetes 15 (5), 871-878, 2021 | 50 | 2021 |
| Substantial fat mass loss reduces low-grade inflammation and induces positive alteration in cardiometabolic factors in normal-weight individuals HV Sarin, JH Lee, M Jauhiainen, A Joensuu, K Borodulin, S Männistö, ... Scientific Reports 9 (1), 3450, 2019 | 50 | 2019 |
| Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study G Rudofsky, AM Catarig, L Favre, K Grau, S Häfliger, R Thomann, ... Diabetes Research and Clinical Practice 178, 108931, 2021 | 39 | 2021 |
| Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups JF Yale, U Bodholdt, AM Catarig, S Catrina, A Clark, NR Ekberg, U Erhan, ... BMJ Open Diabetes Research and Care 10 (2), e002619, 2022 | 34 | 2022 |
| Use of once‐weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE C anada multicentre, prospective, observational study JF Yale, AM Catarig, K Grau, S Harris, A Klimek‐Abercrombie, ... Diabetes, Obesity and Metabolism 23 (10), 2269-2278, 2021 | 33 | 2021 |
| Real-world use of once-weekly semaglutide in type 2 diabetes: results from the SURE UK multicentre, prospective, observational study P Holmes, HE Bell, K Bozkurt, AM Catarig, A Clark, A Machell, ... Diabetes Therapy 12, 2891-2905, 2021 | 28 | 2021 |
| Efficacy of once-weekly semaglutide vs empagliflozin added to metformin in type 2 diabetes: patient-level meta-analysis I Lingvay, MS Capehorn, AM Catarig, P Johansen, J Lawson, A Sandberg, ... The Journal of Clinical Endocrinology & Metabolism 105 (12), e4593-e4604, 2020 | 25 | 2020 |
| An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg RE Pratley, AM Catarig, I Lingvay, A Viljoen, A Paine, J Lawson, B Chubb, ... Diabetes, Obesity and Metabolism 23 (11), 2513-2520, 2021 | 23 | 2021 |
| Once‐weekly semaglutide use in patients with type 2 diabetes: real‐world data from the SURE Italy observational study R Napoli, C Berra, AM Catarig, C Di Loreto, E Donatiello, TL Berentzen, ... Diabetes, Obesity and Metabolism 25 (6), 1658-1667, 2023 | 22 | 2023 |
| Real-world use of once-weekly semaglutide in type 2 diabetes: results from semaglUtide real-world evidence (SURE) Germany M Menzen, TL Berentzen, AM Catarig, S Pieperhoff, J Simon, S Jacob Experimental and Clinical Endocrinology & Diabetes 131 (04), 205-215, 2023 | 20 | 2023 |
| Once-weekly semaglutide use in type 2 diabetes: real-world data from the SURE Netherlands observational study BHR Wolffenbuttel, MP Brugts, AM Catarig, A Clark, M Kok, AG Lieverse, ... Advances in therapy 40 (3), 920-933, 2023 | 18 | 2023 |
| Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study C Skriver, S Friis, LB Knudsen, AM Catarig, AJ Clark, C Dehlendorff, ... Diabetologia 66 (11), 2007-2016, 2023 | 17 | 2023 |
| Once‐weekly semaglutide use in patients with type 2 diabetes: results from the SURE France multicentre, prospective, observational study K Mohammedi, N Belhatem, TL Berentzen, AM Catarig, L Potier Diabetes, Obesity and Metabolism 25 (7), 1855-1864, 2023 | 15 | 2023 |
| Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE Spain multicentre, prospective, observational study V Bellido, C Abreu Padín, AM Catarig, A Clark, S Barreto Pittol, E Delgado Journal of Clinical Medicine 11 (17), 4938, 2022 | 15 | 2022 |
| Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses RE Pratley, VR Aroda, AM Catarig, I Lingvay, J Lüdemann, E Yildirim, ... BMJ open 10 (11), e037883, 2020 | 14 | 2020 |
